Cell-cell interaction in graft rejection responses: induction of anti- allo-class I H-2 tolerance is prevented by immune responses against allo-class II H-2 antigens coexpressed on tolerogen by unknown
Cell-Cell Interaction in Graft Rejection Responses: 
Induction of Anti-Allo-Class I H-2 Tolerance Is 
Prevented by Immune Responses against Allo-Class II 
H-2 Antigens Coexpressed on Tolerogen 
By  Seiji Hori,  Satoru  Kitagawa,  Hisashi  Iwata,  Takenori Ochiai,* 
Kaichi  Isono,*  Toshiyuki Hamaoka,  and Hiromi Fujiwara 
From the Biomedical Research Center, Osaka  University Medical School, 2-2,  Yamadaoka, 
Suita,  Osaka  565; and  *The Second Department of Surgery, Chiba  University Medical 
School, Inokana, Chiba 280, Japan 
Sumanary 
The intravenous sensitization of C57BL/6 (B6) mice with class I H-2-disparate B6-C-H-2  bin1 
(bml) spleen ceils results in almost complete abrogation of anti-bml CD8 + helper (prolifera- 
tive and interleukin 2-produdng) T  cell (Th) activities.  Although an appreciable portion of 
CD8 + cytotoxic T lymphocyte (CTL) precursors themselves remained after this regimen, such 
a residual CTL activity was eliminated after the engrafting of bml grafts,  and these grafts ex- 
hibited prolonged survival.  In contrast, the intravenous sensitization with (bin1  x  B6-C-H- 
2  bmlz [bm12])F1 cells instead of bin1 cells failed to induce the prolongation of bml graft sur- 
vival as well as bin12 and (bin1  x  bm12)F1 graft survival. In the (bml  x  bm12)Fl-presensitized 
B6 mice before as well as after the engrafting of bin1 grafts, anti-bml CTL responses that were 
comparable to or slightly stronger than those observed in unpresensitized mice were induced 
in the absence of anti-bml Th activities, bml graft survival was also prolonged by intravenous 
presensitization with a mixture of bml and bm12 cells but not with a mixture of bin1 and (bml 
x  bm12)F1 cells. The capacity of CD4 + T calls to reject bm12 grafts was eliminated by intra- 
venous presensitization with antigen-presenting cell (APC)-depleted bm12 spleen cells. How- 
ever, intravenous presensitization with APC-depleted (bml  x  bm12)F1 cells failed to induce the 
prolongation ofbml graft survival under conditions in which appreciably prolonged bm12 graft 
survival was induced. More surprisingly, bml graft survival was not prolonged even when the 
(bml  x  bm12)F1 cell presensitization was performed in CD4 + T cell-depleted B6 mice. This 
contrasted with the fact that conventional class I-disparate grafts capable of activating sdf Ia-restricted 
CD4 § as well as aUo-class I-reactive CD8 + Th exhibited prolonged survival in CD4 + T cell- 
depleted, dass I-disparate cell-presensitized mice. These results indicate that: (a) intravenous presen- 
sitization with class I- and II-disparate cells fails to reduce anti-allo-dass I rejection responses 
that would otherwise be eliminated using only dass I-disparate cells; (b) such failure is generated 
according to the coexpression of both classes of alloantigens on a single cell as tolerogen; and 
(c) aUo-dass II antigens coexpressed  on tolerogen function to activate CD4 + as well as non- 
CD4 § Th leading to the generation of anti-class I effector T  cell responses. 
~  immune response to antigen is, in general, modulated 
by various factors/conditions, including the route via 
which antigen is introduced into an individual (1). The pre- 
sentation of alloantigens via the intravenous route regulates 
positively or negatively the induction of anti-allo-immune 
responses. This has been reported for the effect of donor-specific 
transfusion (DST) 1 in humans (1-8) as well as for the effect 
1Abbreviations used in this lmper: DSP, donor-specific  intravenous  presen- 
sitization; DST, donor-specific transfusion;  FMF, flow microfluorometric; 
SN, supernatants. 
of donor-specific intravenous presensitization (DSP) with al- 
logeneic cells in animal studies (9-17). 
The fact that there are different outcomes after DST/DSP 
depends on the disparity of the donor-host combination as 
well as the blood cell component used for the intravenous 
presensitization (11-14, 16, 17). For example, we have demon- 
strated that the DSP of C57BL/6  (B6) mice with class I 
H-2-disparate allogeneic cells (B6-C-H-2  sin1 [bml]) resulted 
in the abrogation of CD8 + Th activity against the bml al- 
loantigens (15) and produced prolonged survival ofbml skin 
graft  (16). In  contrast,  DSP  with  class  II  H-2-disparate 
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duce tolerance of CD4 + Th reactive  to bml2 alloantigens 
(17). These findings indicated that similar protocols of im- 
munomodulation produce distinct effects on the capacity of 
CD8 + and CD4 + Th subsets.  The combination of class I 
and class II H-2 disparities induces heterogenous subsets of 
Th (18-20).  Therefore, the above observations raise the ques- 
tion of whether anti-class I and class II immune pathways 
are independently affected by DSP with class I- and dass II-dis- 
parate cells, or whether the effect of DSP on one pathway 
is influenced by an alternative pathway. Investigating such 
a DSP effect could contribute to a better understanding of 
DSP/DST-induced complicated immunomodulation in the 
combinations with a complex disparity. 
The  present  study was  undertaken  to  investigate how 
anti-class I H-2 (bml) rejection responses are modulated when 
class I- and class II-disparate (bin1  x  bm12)Ft cells, which 
also  have the potential to induce anti-class II immune re- 
sponses,  are used for DSP instead of only class I-disparate 
(bin1)  cells. The results demonstrate that DSP of B6 mice 
with bml cells resulted in the reduction of anti-bml rejection 
responses  along with the elimination of anti-bin1  CD8 § 
Th activity. In contrast, the DSP protocol using (bml  x 
bm12)Fa cells instead of bml cells failed to reduce anti-bml 
rejection potential under conditions in which anti-bml Th 
activity was eliminated similarly to the effect of DSP with 
bin1 cells. The rejection ofbml grafts in B6 mice after DSP 
with (bml  x  bm12)F1 calls was associated  with a potent 
induction of anti-bin1 CTL responses. This contrasted with 
the suppressed  CTL generation in B6 mice receiving DSP 
with bin1 cells, suggesting that potent CTL responses  are 
induced  by  cellular  interactions  between  anti-bin1  CTL 
precursors and anti-bm12 Th. It was also found that the gener- 
ation of anti-bin1 CTL and graft rejection responses  were 
not induced when a mixture ofbml and bin12 cells was used 
for DSP instead of (bml  x  bm12)F1 cells. These results in- 
dicate that an immune response  against a given alloantigen 
that would otherwise be tolerized by DSP with cells expressing 
only the alloantigen is activated through the introduction 
of DSP-resistant immune responses to other alloantigens coex- 
pressed on DSP cells. The results are discussed in the context 
of the nature of the DSP-resistant  immune responses. 
Materials and Methods 
Mice.  C57BL/6 (B6) and BALB/c mice were purchased from 
Shizuoka Experimental Animal Laboratory. B6-C-H-2  ~I (bin1), 
B6-C-H-2  bran (bin12), and B10.QBR mice were originally pro- 
vided by Dr. D. H. Sachs (National Cancer Institute, Bethesda, 
MD). These three strains of mice and hybrid (bml  x  bm12)F: 
mice were bred in our laboratory. These mice were used for experi- 
ments at 7-9 wk of age. 
Intravenous Presensitizaa'on with Allogeneic Cells.  Mice were in- 
jected with 107 allogeneic bml or (bml  ￿  bm12)F1 spleen cells 
via the intravenous route. 
Media Used for In Vitro Cell Culturing.  Culture medium used 
for the MLR was RPMI 1640 supplemented  with 10% horse serum, 
5  x  10 -5 M 2-ME, sodium pyruvate, glutamine, nonessential 
amino acids, and 5 mM Hepes buffer. Complete medium for the 
generation of CTL was prepared by replacing 10% horse serum 
with 10% FCS. RPMI 1640 supplemented with 5% FCS plus 5 
x  10 -s M 2-ME was used for the production of II,-2 and IL-2 
assays. 
Monodonal Antibodies.  Anti-CD4 (GK1.5) (21) and anti-CD8 
(3.155) (American  Type  Culture Collection, Rockville,  MD) mAbs 
were obtained from culture superuatants of hybridomas  producing 
the relevant antibody. GK1.5 mAb was also obtained in the form 
of ascitic fluid. A gamma globulin fraction of the ascitic fluid was 
obtained by precipitation at 50% saturation with ammonium sul- 
fate and used for in vivo administration. 
Mixed Lymphocyte Reaction.  The responding lymph node ceils, 
obtained from a pool of three to five animals per group, were 
resuspended in complete medium and cultured at a concentration 
of 2  x  105 cells per culture well together with 4  x  105 irradi- 
ated (2,000 tad) stimulating spleen cells in a total volume of 0.2 
ml (15-17). Each MLR was performed in triplicate  in fiat-bottomed 
microculture  plates (Coming  25860; Coming  Glass Works, 
Coming, NY) and maintained in humidified atmosphere at 5% 
CO2 at 37~  The cultures were harvested onto glass fiber filters 
with an automatic cell harvester at 96 h after an 8-h pulse with 
20 KBq/well of [3H]TdK. Radioactivity was determined by liquid 
scintillation spectrometry. Results were calculated from the up- 
take of [3H]TdR and expressed as the mean uptake in cpm _+ SE 
of triplicate cultures. 
Generation of Cytotoxic T Lyrnpbocytes.  CTL induction was per- 
formed as previously described (22). Briefly, 4 or 5  x  105 spleen 
cells were cultured in vitro with 105 irradiated (2,000 tad) syn- 
geneic or allogeneic spleen cells in 24-well culture plates (Coming 
25820; Coming Glass Works) in a volume of 2 ml at 37~  for 
various periods. Effector ceils generated were assayed on SlCr- 
labeled target cells (spleen cells cultured for 48 h with Con A, 5 
/zg/ml). Percent specific  lysis was calculated as described (22). SE 
in each group were <10% and these were excluded from figures 
for simplicity. 
Production of  ll.,2 and Assa 7 System for 11.,2 Activity.  Spleen  cells 
(5  ￿  105) were cultured with 3  x  105 syngeneic or allogeneic 
stimuhtor spleen ceils (2,000 tad) in 24-well  culture plates (Coming 
25820; Coming Glass Works) in a volume of 1 ml (15-17). After 
incubation at 37~  in a humidified incubator (5% COz) for 48 h, 
culture supematants (SN) were harvested by centrifugation and 
stored at  -20~  until use. 
SN were assayed for Ib2 activity according to their ability to 
support the proliferation of  the II~2-dependent  T cell line, CTLD2 
(15-17). CTLL-2 (10Uwell) were cultured with SN in a volume 
of 0.2 ml in 96-well fiat-bottomed microplates (Coming 25860; 
Coming Glass Works) for 24 h at 37~  Proliferation was assessed 
by the  uptake  of [3H]TdR during 4-h  pulsing  with 20  KBq 
[~H]TdR/well. 
Skin Grafting of  B6 Mice.  Mice  were engrafted on the flank with 
tail skin grafts according to an adaptation of the method of  Billing- 
ham and Medawar (23). Bandages were removed on day 7 and the 
grafts were scored daily until rejection (defined as loss of >80% 
of the grafted tissue). 
Depletion of Mac-1 § Cells (APC) from Spleen Cells.  A single cell 
suspension of spleen cells was depleted of Mac-1  + cells (APC) by 
two round passages over Sephadex G-10 columns as described by 
Ly and Mishell (24). Depletion of Mac-1  + cells (<1%) was con- 
firmed by flow microfluorometric (FMF) studies using anti-Mac-1 
mAb (M1/70). 
Depletion ofCD4 + T Cells.  The procedure was the same as de- 
scribed (25). Semipurified anti-CD4  antibody (GK1.5) was ad- 
ministered in vivo at the dose of 100/~g/d three times/wk.  Ad- 
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Figure 1.  Suppression of anti-bin1 
MLIL capacity by DSP with (bin1  x 
bm12)F1 ~  ]36 mice were injected in- 
travenously with 10  7 bml or (bin1  x 
bm12)F1  cells (DSP).  1  wk  later, 
lymph no& cells (2 x  106) from these 
presensidzed and unpresensitized B6 
mice were stimulated in vitro with it. 
radiated spleen cells (4  x  106) from in- 
dicated strains of mice for 96 h in 96- 
well microculture plates. 
ministration of the antibody for >2 wk resulted in almost complete 
elimination of CD4 + T  ceils as revealed by FMF study (25,  26). 
Results 
Suppression of Anti-bral  Th Activities  by DSP with bin1 or 
(bml  ￿  bm12)F1 Spleen Cells.  B6 mice were presensitized 
intravenously with 10  7 bin1 or (bml  x  bm12)F1 spleen cells 
(DSP).  1 wk after DSP,  lymph node cells from these mice 
were tested for their ability to proliferate upon in vitro stim- 
ulation  with bin1,  bm12,  or BALB/c  spleen cells  (MLtL). 
As shown in Fig.  1, lymph node cells from either bin1- or 
(bin1  x  bm12)Ft-presensitized B6 mice exhibited markedly 
reduced anti-bin1 MLR. Spleen cells from the same presensi- 
tized mice as used in Fig. 1 were also tested for their capacity 
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Figure 2.  Suppression of anti-bin1 IL-2 production by DSP with (bml 
x  bml2)Fl cells. Spleen cells (5  x  10  6) from the same mice as used in 
Fig. 1 were cultured with irradiated stimulator spleen ceLls (3  ￿  106) in 
24-well plates. SNs were assayed  for IL,2 activity using the IL-2-dependent 
cell line, CTLD2. 
101  Hori et al. 
60 
40 
U)  ￿9  ~  20 
r  0  om  N'-  ,D 
O 
(n 
o  ~  4o 
20 
Symbol  DSP with: 
........  (-) 
O  O  bml 
(bml x bm12)F1 
E:T=10'I  E:T=5:I 
......  .  .,,/." o 
B 
.j 
I 
C  "  , 
1  2  3  4  5 
D 
r 
1  2  3  4  5 
Period of cultures 
Figure 3.  Enhanced anti-bml CTL potential in mice presensitized with 
(bml  x  bm12)Ft cells. Spleen cells (4  x  106) from unpresensitized mice 
or mice presensitized with bml or (bin1  x  bm12)Ft cells were stimu- 
lated in vitro with irradiated bin1 (A and B) or BALB/c (control) (C and 
D) spleen cells (106) in 24-well culture plates for 1-5 d. Responding cells 
recovered various days after cuhuring (effector cells) were tested for their 
anti-bml (A and B) or anti-BALB/c (C and D) cytotoxic activity on bin1 
or BALB/c blast target cells at E/T ratios of 10:1 and 5:1. to produce IL-2 upon stimulation with bml or bml2 alloan- 
tigens (Fig. 2). The results demonstrate that DSP with cells 
expressing bml antigens resulted in a reduction of the ca- 
pacity to produce II.-2 in response to the stimulation with 
bin1 alloantigens,  and also indicate that DSP with bml or 
(bin1  x  bm12)Ft cells eliminates anti-bml Th activities  as 
measured by MLR and I].-2 production. 
Enhanced Induction of  Anti-bml CTL Responses by Spleen Cells 
from B6 Mice after DSP with (brnl  x  bm12)F1 Cells.  To de- 
termine the effect of DSP with bin1 or (bml  x  bm12)Ft 
cells on the ability to generate anti-bml CTL responses, spleen 
cells from bin1- or (bin1  x  bm12)Ft-presensitized mice were 
stimulated in vitro with bin1  or BALB/c  (control) cells. 
Effector cells generated various periods (1-5 d) later were as- 
sayed on bin1 or BALB/c blast target cells (Fig. 3). The results 
demonstrate that spleen cells from bml-presensitized B6 mice 
produce anti-bml CTL responses, but the CTL activity is 
appreciably weaker compared to that obtained with normal 
B6 spleen cells, which confirms our previous results (16). In 
contrast, DSP with (bin1  x  bm12)F1 cells resulted in a con- 
siderably enhanced generation of anti-bin1 CTL responses 
when responding ceUs from these presensitized mice were 
stimulated in vitro with bin1 cells. The results of Fig. 3 also 
illustrate that such modulation was specific for anti-bin1 CTL 
responses, since comparable magnitudes of anti-BALB/c CTL 
responses were generated by spleen cells from either normal, 
bml-presensitized,  or  (bin1  x  bm12)F1-presensitized  B6 
mice. Thus, DSP of B6 mice with (bin1  x  bm12)F1 cells 
results in the enhancement of anti-bin1 CTL potential along 
with almost complete elimination of anti-bin1 Th activity. 
Differential Effects of DSP with bin1 vs. (bmI  x  brnl2)F1 
Cells on brnl Graft Survival.  We next investigated the effects 
of DSP with (bin1  x  bml2)F1 cells on the generation of 
anti-bin1 graft rejection responses. The finding shown in Fig. 
4 (a part of results) confirms that DSP orB6 mice with bin1 
cells induces prolongation ofbml graft survival. In contrast, 
when DSP was performed using (bin1  x  bm12)F1 calls, the 
prolongation of bin1 graft survival was not observed,  but 
rather a slightly accelerated graft rejection was seen. 
We examined anti-bin1 T cell (Th and CTL) responsive- 
ness in B6 mice engrafted with bml grafts after DSP with 
(bin1  x  bml2)F1 cells (Table 1 and Pig.  5). The results of 
Table 1 demonstrate that lymph node cells from B6 mice en- 
grafted with bin1 grafts (7-d graft bearing) after DSP with 
either bml or (bin1  x  bm12)F1 cells exhibit the suppres- 
sion of anti-bin1 Th (MI.R and IL-2 production) activities 
on one hand. On the other, spleen cells from bml- or (bml 
x  bm12)Frpresensitized mice  7  d  after  bml-engrafting 
generated markedly reduced or potent (slightly higher) anti- 
bin1 CTL responses when compared with those obtained by 
unpresensitized, bin1 skin-bearing control mice (Fig. 5). These 
results indicate that T cell (Th and CTL) responsiveness as 
observed in  B6  mice receiving only DSP  with  (bin1  x 
bm12)F1 cells continues after engrafting of bml skin grafts. 
Taken together with the results of Fig. 4, Table 1, and Fig. 
5, the failure of (bml  x  bm12)Fl-presensitized mice to in- 
duce the prolongation ofbml graft survival is associated with 
the potent anti-bin1 CTL response that is induced under con- 
ditions in which the suppression of anti-bin1 Th activities 
is continued. 
Suppression of Prolongation of brnl Graft Survival Depends on 
DSP with Cells Coexpressing bral and bra12 Antigens.  The 
preceding observations suggested that a concomitant anti- 
bin12 immune response generated through DSP with (bin1 
x  bm12)F1 cells functioned to prevent the prolongation of 
bin1 graft survival that would otherwise be induced by DSP 
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Figure 4.  Survival  of bml skin graft 
on B6 mice presensitized with bml or 
(bin1  ￿  bm12)F1 cells. B6 mice were 
presensitized  intravenously  with  10  ~ 
bml or (bin1  x  bm12)Fl cells. 1 wk 
later, these presensitized and unpresen- 
sitized mice were engrafted with bml 
grafts. Table  1.  Suppression of Anti-bral  Th Activities in B6  Mice Engrafted with  bral Grafts after DSP with  bml  or (bral  ￿  bm12)F, Cells 
Responding cells from B6 mice 
[3H]TdlL uptake (cpm,  x 10 -3) after stimulation with: 
DSP  engrafted 
Assay*  with:  with:  B6  bml  BALB/c 
MLR 
IL-2 production 
-  bml  2.6  _+  1.0  29.6  _+  1.0  26.5  +  0.7 
bml  bml  3.7  _+ 0.1  4.4  +  0.4  24.1  _+ 0.4 
(bml  x  bm12)Fl  bml  3.5  _+  0.1  8.5  +  0.1  19.3  _+ 0.7 
-  bml  0.3  +  0.0  12.3  _+ 0.7  15.9  +  0.6 
bml  bml  0.2  +  0.0  2.2  _+ 0.1  17.7  +  0.4 
(bml  x  bm12)F1  bml  0.4  _+  0.1  1.2  _+  0.5  13.2  _+  1.0 
* Lymph node cells (for MLR assay) or spleen cells (for IL-2 production) from B6 mice engrafted  with bin1 grafts after DSP with indicated  cells 
were stimulated  with bml or BALB/c  (control) spleen  cells. In IL-2  production,  culture  SNs were assayed  for IL-2  activity  using  the CTLL-2  cell  line. 
with bin1 cells. We further investigated the conditions re- 
quired for the generation of such an anti-bm12 immune re- 
sponse. B6 mice received DSP with either (bml  x  bm12)F1 
cells, a mixture ofbml and bm12 cells, or a mixture ofbml 
and (bin1  x  bm12)F1 cells 1 wk before the engrafting of 
bml grafts. Fig. 6 again shows a slightly accelerated rejec- 
tion of bml grafts by DSP with (bin1  x  bm12)Ft cells. The 
results also demonstrate that: (a) bin1 grafts engrafted in B6 
mice presensitized with a mixture of bml and bm12 cells 
exhibited a comparable degree of prolonged survival to that 
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Figure 5.  The generation  of  potent  anti-bml  CTL responses  by B6 mice 
engrafted  with bin1 after  DSP with (bml x bm12)F1 but not with bin1 
cells. Portions of the same spleen cells as used in the Ib2 production  in 
Table 1 were sensitized  in vitro with bml or BALB/c stimulator cells. 
Effector  cells generated  5 d after  culturing  were assayed  on bml or BALB/c 
blast target cells. 
observed in B6 mice presensitized with bin1 cells (Fig. 4), 
and (b) DSP with a mixture of bml and (bml  x  bm12)F1 
cells failed to induce the prolongation of bml graft survival. 
These findings indicate that the concomitant generation of 
anti-bm12 immune responses  along with DSP leads to the 
prevention of prolongation of bml graft survival,  but this 
is the case only when anti-bm12 responses  are induced by 
bm12 antigens coexpressed  with bmt antigens on a single 
DSP cell. Moreover, these observations also exclude the pos- 
sibility that the failure of (bin1  x  bm12)Ft cells to produce 
the anti-bin1 DSP effect is ascribed to the expression ofbml 
antigens on F1  cells either in an incomplete way or in a 
manner different from that on bml cells. 
Anti-bin12 Non-CD4 + T  Cell-mediated Inhibition  of Anti- 
bin1 DSP Effect.  bm12 antigens have been known to induce 
the activation of Th (prolfferative/II.,2 producing) and T cells 
responsible for anti-bin12 graft rejection that are exclusively 
of CD4 + phenotype (17). An earlier  study from our labo- 
ratory has also demonstrated that DSP of B6 mice with APC- 
depleted bm12 spleen cells (essentially bm12 antigen-expressing 
B cells) but not with whole spleen cells results in the elimi- 
nation of anti-bin12 CD4 + Th and graft rejection-mediat- 
ing T cells (17). Therefore, we finally investigated whether 
the anti-bml DSP effect is inducible even by DSP with (bml 
x  bm12)Ft  cells  under  conditions  in  which  anti-bm12 
CD4 + T cell activity is not induced. B6 mice received DSP 
with various types of cells: (a) bml cells, (b) Sephadex G-10- 
passed bin12 (G-10-bm12), (c) mixture ofbml and G-10-bm12 
cells,  (d)  (bml  x  bm12)F1  cells,  and  (e)  G-10-(bml  x 
bm12)F1 cells. 1 wk later, unpresensitized and these presen- 
sitized B6 mice were engrafted with either bml, bin12, or 
(bml  x  bm12)F1  grafts.  The  results  are  summarized in 
Fig. 7. The results confirm that the anti-bin1 DSP effect is 
not inducible with cells coexpressing bml and bin12 antigens 
(Ibm1  x  bm12]F~ cells) (A) and that DSP with G-10-bm12 
cells induces marked prolongation of bm12 skin graft sur- 
vival (B). Moreover, Fig. 7 provides the following important 
information. First, DSP with a mixture of bml and G-10- 
bm12 cells induces the prolongation of (bml  x  bm12)F1 
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Figure 6.  Compression of bml and bm12 antigens on 
DSP cells is required for blocking anti-bml DSP effect. 
B6 mice were presensitized with either (bin1  x  bm12)F1 
ceUs (107), a mixture of bml (107) and bin12 ceils (107), 
or a mixture of bin1  (107) and (bml  x  bm12)F1 cells 
(107) 1 wk before engrafting bml grafts. 
graft survival (C). These observations exclude the possibility 
of the existence of Frunique antigens (27) that would be 
expressed only on Ft calls but not on bml or bm12 calls. 
This suggests that the blockage of the anti-bml DSP effect 
at the time of DSP with F1 cells is produced through cel- 
lular interactions between anti-bml effector cells and assisting 
(Th) calls directed against bm12 but not against putative F1- 
unique antigens. 
Second, DSP with G-10-(bml  x  bml2)F1 cells was seen 
to induce appreciable levels of prolongation of bm12 graft 
survival. Even under these conditions, however, portions of 
the same DSP cells failed to induce any significant prolonga- 
tion ofbml graft survival (Fig. 7 A). In fact, the bml graft 
rejection in this DSP group was slightly accderated, similar 
to that observed in the (bml  x  bm12)FrDSP group when 
compared with an unpresensitized control group. These results 
indicate that the anti-bml DSP effect is not produced by DSP 
with G-10-F1 cells capable of reducing anti-bin12 CD4 + T 
cell reactivity. This implies the existence of an alternate anti- 
bin12 immune response pathway that influences anti-bin1 re- 
sponses upon DSP with F1 or G-10-F~ ceils. 
Additional experiments were performed to confirm that 
anti-bm12 responses involved in the blockage of the anti-bml 
DSP  effect  do  not  necessarily  bdong  to  the  CD4 +  Th 
subset. B6 mice were depleted of CD4 + T ceUs by injecting 
semipurified anti-CD4 (GK1.5) antibody at the dose of 100 
~g/d three times per week as previously described (25, 26). 
This procedure was capable of almost completely eliminating 
CD4 + T  calls when continued for 2 wk (six times) (data 
not shown here but detailed in references 25 and 26). B6 mice 
were given the anti-CD4 antibody according to the above 
protocol 1 wk after the initiation of anti-CD4 injections, 
B6 mice were presensitized with untreated or G-10-passed 
(bml  x  bm12)Ft cells, and 1 wk later, engrafted with bml 
skin grafts. The administration of the anti-CD4 antibody was 
continued until the grafts were rejected. The results are shown 
in Fig. 8 A. The anti-CD4 administration failed to produce 
the anti-bml  DSP effect  after  DSP with either (bml  x 
bm12)Fa  or G-10-(bml  x  bm12)F1 cells. This contrasted 
with the beneficial effect of the anti-CD4 treatment on the 
prolongation of graft survival in two other control combi- 
nations (Hg. 8, B and C): the B6-bm12 combination in which 
allo-class II H-2-restricted CD4 + Th (graft rejeFtion-initi- 
ating T calls) are functioning and the B6-B10.Q_,R combi- 
nation with class I H-2 disparity in which self class II H-2- 
restricted CD4 + Th and allo-class I H-2-restricted CD8 + 
Th are functioning along with CD8 + CTL precursors.  In 
the former combination, the administration of anti-CD4 an- 
tibody resulted in striking prolongation of bm12 graft sur- 
vival (Fig. 8 B). In the latter, prolongation of B10.QBR grafts 
was not induced by either DSP with B10.QBR cells or anti- 
CD4 treatment. However,  the combination of these treat- 
ments  produced an  appreciable  level  of prolongation  of 
B10.QBR graft survival, which is consistent with the previous 
finding (26).  In this model, DSP with B10.QBR together 
with the anti-CD4 treatment eliminated the respective allo- 
class I-restricted CD8 + Th and self class II-restricted CD4 + 
Th (see reference 26). The observations in Fig. 8, B and C 
illustrate that the anti-CD4 treatment is capable of eliminating 
various  CD4 + Th subsets  (allo-dass  II restricted and self 
class II restricted).  Taken collectively, the resuhs of Fig. 8 in- 
dicate that an alternate  anti-bm12 immune response that is 
not mediated by the CD4 + T cell subset is activated upon 
DSP with  (bml  x  bm12)F1 cells and that  this response 
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Figure 7.  Differential effects of DSP with untreated or G-10-passed  spleen 
cells on survival of bml, bin12, or (bml x  bm12)F1 grafts. B6 mice were 
presensitized with indicated DSP cells I wk before engrafting  bin1, bin12, 
or (bin1  x  bm12)F1 grafts. 
functions to induce the generation of anti-bml CTL and graft 
rejection responses under conditions in which the classical 
anti-bm12 responses (CD4 + T  cells) are eliminated. 
I~uu]on 
Immune responses to alloantigens are initiated by the rec- 
ognition of alloantigens by helper-type T cells and by their 
subsequent production of various lymphokines capable of ac- 
tivating effector T cells. Therefore, elimination and/or func- 
tional suppression of Th cells lead to an essential immuno- 
modulation of anti-aUo-immune  responses. For example, DSP 
of B6 mice with class I MHC-disparate bml cells results in 
the elimination of anti-bml allo-class 1-restricted CD8 + Th 
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activity (15, 16). Because this represents the abrogation of 
the total Th activity functioning in the B6-bml combina- 
tion, DSP in this combination leads to the reduction of in 
vivo rejection potential and prolongation of graft survival 
(16). In contrast to allo-class I-restricted CD8 + Th, some 
of other Th subsets appear to be resistant to immunomodu- 
lation by DSP (26).  In considering that various subsets of 
Th would function in the donor-host combinations with com- 
plex disparities such as combinations with conventional class 
I and/or class II disparities,  the question has been raised of 
how the immunomodulation of DSP-sensitive responses to 
alloantigen A is influenced by DSP-resistant  responses to al- 
loantigen B upon DSP with cells expressing both A and B 
alloantigens. 
The present study was undertaken to determine how cel- 
lular interactions between different subsets of Th and effector 
T cells influence the production of DSP effects  on each pathway 
of the immune responses. It was demonstrated that: (a) DSP 
of B6 mice with class I-disparate bml cells or class I- and 
class II-disparate (bin1  x  bm12)F1 cells resulted in almost 
complete abrogation of anti-bml Th activity; (b) DSP with 
bml induced prolongation of bin1 graft survival whereas DSP 
with (bml  x  bm12)F1 cells failed to prolong bml graft sur- 
vival; (c) the failure of DSP with (bin1  x  bm12)F1 cells to 
produce anti-bml DSP effect was associated with the enhanced 
induction of anti-bml CTL responses before and after bin1 
skin grafting that was not observed by DSP with bin1 cells; 
(d) DSP with a mixture of bin1 and bm12 cells produced 
an anti-bml DSP effect, indicating that the coexpression of 
both alloantigens on a single DSP cell is necessary to block 
the generation of the anti-bml DSP effect; and (e) surpris- 
ingly, even when the CD4 +  T  cell  subset including the 
major  anti-bm12  Th  is  eliminated,  DSP  with  (bin1  x 
bm12)F, cells failed to prolong bml graft survival. 
The present results would permit discussion from two 
mutually related aspects. First, it was demonstrated that there 
was a fundamental biological difference between DSP using 
cells with only class I- vs. class I  +  class II disparities in the 
suppression of anti-class I MHC responses. It may be worth 
considering that hosts that have been presensitized intrave- 
nously  with  class  I-  and  class II-disparate  ([bml  x 
bm12]Ft) cells possess enhanced potential to reject only class 
I-disparate grafts as well as class I- and II-disparate grafts. 
This enhanced potential would be reflected on potent anti-class 
I (bml) CTL responses generated when spleen cells from the 
(bml  x  bm12)Fvpresensitized host are stimulated in vitro 
with bml cells. Thus, such enhanced anti-class I immune 
potential would be elaborated in the course of DSP with cells 
coexpressing class I and class II antigens on a single DSP cell. 
The production of beneficial DSP/DST effects would there- 
fore be more difficult in donor-host combinations with class 
I and dass II disparities than in class I-disparate, class II-com- 
patible combinations. This is based on the fact that in addi- 
tion to the operation of anti-class II responses themselves, 
these responses function to interfere with the reduction of 
anti-class I responses.  However, even if it is supposed that 
a graft from the (class I  +  class II)-disparate  donor consists 
mostly of class I-positive class II-negative cells, it is impor- 100 
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Figure 8.  Failure of anti-CD4 administration to pro- 
duce  anti-bml DSP  effect after  DSP  with  (bml  x 
bm12)Ft ceUs. B6 mice were given anti-CD4 antibody 
(100/~g/time,  three times/wk). 1 wk after initiation of 
anti-CD4 administration,  these mice were not presensi- 
tized or were presensitized with indicated strains of spleen 
cells. 1 wk later, these mice were engrafted with grafts 
from indicated strains of mice. 
tant to note that anti-class I immune reactivity is enhanced 
at the timing of DSP/DST. 
The second aspect is concerned with the nature of anti- 
bm12 responses that would function to enhance anti-bin1 CTL 
responses along with DSP with (bin1  x  bm12)F1 cells. It 
is reasonable to assume that the suppression of the anti-bml 
DSP effect upon DSP with (bin1  x  bm12)Fi cells is pro- 
duced by the introduction of some element(s) of anti-bm12 
reactivity.  In general, anti-bm12 T cell responses have been 
found to be mediated exclusively by the CD4 + T cell subset 
(17, 20). The function of this T cell subset includes the ca- 
pacities to induce MLR/II.-2 production in vitro (17, 20) and 
to initiate graft rejection in vivo (20). DSP of B6 mice with 
bm12 spleen cells failed to eliminate these capacities. How- 
ever, they were almost completely eliminated by DSP with 
APC-depleted bm12 spleen cells (bm12 B cells) (20, 28). While 
taking these findings into consideration, the present study 
sought  to  determine  whether  APC-depleted  (bml  x 
bm12)F1 spleen cells function to produce the anti-bml DSP 
effect. The results demonstrated that DSP with APC-depleted 
(bin1  x  bm12)F1 (G-10-[bml  x  bm12]F1) cells induced ap- 
predable levels of the anti-bm12 DSP effect, as observed by 
the prolongation of bm12 skin graft survival.  Even under 
these conditions, however, the same regimen failed to pro- 
duce an anti-bml DSP effect. More surprisingly, the anti- 
bml DSP effect was not produced in CD4 + T cell-depleted 
B6 recipient mice when (bin1  x  bm12)Fi cells were used 
as DSP donor cells. It is unlikely that an immune response 
to Fvunique antigen (27) is involved in the blockage of the 
anti-bml DSP effect, because such a response is not detected 
in B6 mice depleted of anti-bml and -bm12 responses (Fig. 7 
C). Alternatively, the above observations may also suggest 
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involved in the enhanced generation of anti-bml CTL as 
well as graft rejection potential upon DSP with (bin1  x 
bm12)F1 cells. 
Three major Th subsets have been described as functioning 
in the recognition of allo-dass I and -class II MHC antigens 
(19).  These include:  (a)  allo-dass  1-restricted  CD8 +  Th 
(e.g.,  anti-bml Th);  (b)  allo-dass II-restricted CD4 + Th 
(e.g., anti-bin12 Th); and (c) self dass II-restricted allo-dass 
I-reactive CD4 + Th (although a bml mutant dass I antigen 
does not induce this type of Th, they are commonly induced 
in combinations with conventional class I-disparities;  refer- 
ences 26 and 29). Thus, two types of Th (a and b) are consid- 
ered to function in the B6-(bml  x  bm12)F1 combination 
(16, 17). We have found di~culty in understanding the present 
results in terms of the above-described idea. Several groups 
of investigators have described the existence of CD4 + and 
CD8 + CTL reactive to allo-dass II MHC antigens (30-32). 
Moreover, Shinohara et al. (33) found that some of these CTL 
recognize class II alloantigens in the context of self MHC 
antigens (33), indicating that there exist CTL subsets that 
differ from one another in their phenotype and mode of al- 
loantigen recognition. Likewise,  the possibility can not be 
ruled out that additional distinct subsets of Th exist to be 
activated with class I or class II alloantigens.  In this context, 
some of our recent findings regarding the establishment of 
phenotypically and functionally heterogenous bm12-specific 
Th clones  appear  relevant  (Iwata,  S.,  A.  Kosugi,  and H. 
Fujiwara, manuso'ipt in preparation). An anti-bm12 Th line 
was established  from long-term cultures of B6 spleen cells 
with irradiated bm12 spleen cells. By subsequent cell cloning, 
30 bm12-specific cloned lines were obtained. Approximately 
90%  of these  T  cell  clones were  CD4 +  with  a  highly 
proliferative capacity, whereas the rest were mildly prolifera- 
tive CD8 +. These observations demonstrated the existence 
of anti-bm12 Th clones that have not been described previ- 
ously. The postulation that such anti-bm12 CD8 + Th func- 
tioned to assist anti-bml CTL responses upon DSP with (bin1 
x  bm12)F1 cells could account for the enhanced generation 
of anti-bml CTL potential under the conditions of complete 
CD4 + T  cell depletion. 
Even though anti-bm12 responses consist of distinct subsets 
of Th, their characteristics  will also have to be taken into 
consideration in comparison with those of other Th subsets. 
Earlier studies from our laboratory focused on the heteroge- 
neity of CD8 + and CD4 + Th functioning in conventional 
class I-disparate combinations according to their DSP sus- 
ceptibility as well as their capacity to exhibit MLR (26, 29). 
The  results  demonstrated that:  (a)  allo-dass  1-restricted 
CD8 + Th had potent proliferative (MLR) capacity and were 
highly susceptible to DSP (29), as has been observed for anti- 
bin1  CD8 +  Th  (16); (b)  self dass  II-restricted allo-dass 
I-reactive CD4 + Th consisted of highly proliferative and less 
proliferative  (undetectable in MLR) subsets  (26) that were 
susceptible  and resistant  to DSP, respectively  (29);  and (c) 
the former CD4 + Th subset could function to initiate graft 
rejection without activating CTL precursors (CTbindepen- 
dent graft rejection pathway), whereas the latter functioned 
exclusively as Th assisting CTL responses (CTL-Th) (29). As 
an analogy to this, it may be possible  to speculate  on the 
heterogeneity of allo-dass II-reactive Th subsets from their 
phenotypes as well as their DSP susceptibility and MLR ca- 
pacity.  Allo-dass II-restricted CD4 + Th with highly pro- 
liferative capadty (classical anti-bm12 CD4 § Th) have been 
found to be susceptible to DSP with B cells, but not with 
APC, expressing bm12 aUoantigens (28). It appears that these 
Th cells function to initiate the CTI.-independent graft re- 
jection pathway in a manner similar to self class II-restdcted 
allo-dass I-reactive CD4 + Th with potent MLR capacity. 
Regarding the above allo-class II-reactive CD8 + anti-bin12 
Th subset, it remains unclear how numerous these Th cells 
are among bulk spleen cells. However, if we assume that they 
function as CTL-Th and are resistant to DSP just as self class 
II-restricted allo-dass I-reactive CD4 § Th with less pro- 
liferative capacity, the present results may be more easily un- 
derstood. In this postulation, this subset of Th (CTL.Th) in 
B6 recipient mice might be visualized as being resistant to 
DSP with (bin1  x  bm12)F1 cells and functioning to assist 
the activation of anti-bml CD8 + CTL precursors. Such cell- 
cell interaction would occur even in CD4 + T cell-depleted 
recipient mice. It is also conceivable that in the B6-bm12 com- 
bination, this subset of Th would neither be detectable in 
MLR nor function in anti-bin12 graft rejection due to a lack 
of sut~dent anti-bm12 CTL precursors. 
￿9  In conclusion, the present study illustrates that compared 
to the disparity at only dass I MHC, the disparity at class 
I and class II MHC induces a more potent activation of anti- 
dass I CTL and graft rejection responses through the introduc- 
tion of anti-class II Th capable of assisting  anti-class I re- 
sponses. Further, the suppression of the anti-class I response 
that would otherwise be induced by DSP in only dass I dis- 
parity is blocked upon DSP in the class I +dass II--disparate 
combination through more complicated cellular interactions. 
Finally, the anti-class II response involved in such cellular 
interactions is regarded as a new type of Th that has as yet 
not been observed in the dass II--disparate  combination. Thus, 
by demonstrating that there exists a new pathway of anti-class 
II responses leading to the activation of anti-class I responses 
through cellular interactions, and that such a pathway in- 
duces complicated modulation of anti-class I graft rejection 
potential at the timing of DSP, the present study could pro- 
vide important insights into transplantation immunology. 
107  Hofi et al. The authors are grateful to Miss Misaki Kanagawa for her expert secretarial assistance. 
This work was supported in part by Grant-in-Aids for Scientific Research from the Ministry of Public 
Welfare, Japan. 
Address correspondence  to Hiromi Fujiwara,  Biomedical  Research Center, Osaka University  Medical  School, 
2-2, Yamadaoka, Suita, Osaka, 565, Japan. 
Received for publication 26 July 1991. 
~erellces 
1.  Siskind, G.W. 1984. Immunologic tolerance. In Fundamental 
Immunology. W.E. Paul, editor. Raven Press, New York. pg. 
537. 
2.  Opelz, G., D.P.S. Sengar, M.R. Mickey,  and P.I. Terasaki. 1973. 
Effect of  blood transfusions on subsequent kidney transphnts. 
Transplant. Proa 5:253. 
3.  pestenstein, H., J.A. Sachs, A.M.I. Paris, G.D. Pegrum, and 
J.F. Moorhead. 1976. Influence of HLA matching and blood- 
transfusion on outcome of 502 London transplant group renal- 
graft recipients. Lancet. 1:157. 
4.  Vincenti, E, R.M. Duca, W. Amend, H.A. Perkins, K.C. 
Cochrum, NJ. peduska, and O. Salvatierra,  Jr. 1978. Immuno- 
logic factor determining survival  of  cadaver-kidney  transplants: 
the effect of HLA serotyping, cytotoxic antibodies, and blood 
transfusions on graft survival. N. Engl. f  Med. 299:793. 
5.  Leivestad, T., A. Flatmark, H. Hirschberg, and E. Thorsby. 
1982. Effect  ofpretransplant donor-specific  transfusions  in renal 
transplantation. Transplant. Proa 14:370. 
6.  Salvatierra, O. Jr., Y. Iwaki, F. Vincenti, W. Amend, P. Ter- 
asaki, M. Garovoy,  R. Duca, S. Hopper, and N. peduska. 1982. 
Update of the University of California at San Francisco ex- 
perience with donor-specific  blood transfusions. Transplant.  Proa 
14:363. 
7.  Schweizer, R., L. Bow, D.A. Generas, and S. Bartus. 1982. 
Serologic considerations in donor-specific  transfusion therapy 
for kidney transplantation. Transplant. Proa 14:374. 
8.  Takahashi, I., O. Otubo,  M. Nishimura, T. Yanagisawa, H. 
Nozaki, H. Sugimoto, Y. Kusada, Y. Yamada,  J. Yamanchi, 
A. Sakai, and T. Inoue. 1982. Prolonged  graft survival  by donor- 
specific blood transfusion (DSBT). Transplant. Proa 14:367. 
9.  Fabre,  J.W., and p.J. Morris. 1972. Effect  of  donor strain blood 
pretreatment on renal allograft rejection in rats. Transplanta- 
tion (Baltimore). 14:608. 
10.  Okazaki, H., T. Maki, M. Wood, and A.P. Monaco. 1980. 
Effect of a single transfusion of donor-specific  and nonspecific 
blood on skin allograft survival in mice. Transplantation  (Balti- 
more). 30:421. 
11.  Niessen, GJ., R.L. Marquet, A.B. Bijnen, H. Obertop, and 
J. Jeekel. 1982. The effect of  cyclosporin  A and blood transfu- 
sion on cardiac allograft survival in rats. Surgery (St. Louis). 
91:339. 
12.  Wood, M.L., and A.P. Monaco. 1984. Introduction  of un- 
responsiveness to  skin ailografts in adult mice disparate at 
defined  regions of  the H-2 complex. II. Effect  of  pre-grafr donor 
specific blood transfusions in ALS-treated mice. Transplanta- 
tion (Baltimore). 37:39. 
13. Jenkins, A. McL., and M.F.A. Woodruff. 1971. The effect of 
prior administration of donor strain blood or blood constitu- 
ents on the survival of  cardiac aUografts  in rats. Transplantation 
(Baltimore). 12:57. 
14.  Wood, KJ., J. Evins, and p.J. Morris. 1985. Suppression of 
renal allograft  rejection in the rat by class I antigens on purified 
erythrocytes. Transplantation (Baltimore). 39:56. 
15.  Sato, S., T. Azuma, J. Shimizu, J. Shima, S. Kitagawa, T. 
Hamaoka, and H. Fujiwara. 1988. Property of class I H-2 
aUoantigen-reactive Lyt-2  + helper T cell subset: abrogation of 
its proliferative and IL2-prodncing capacities by intravenous 
injection of class I H-2-disparate allogeneic ceils,  f  Immunol. 
141:721. 
16.  Azuma,  T.,  S.  Sato, S.  Kitagawa, S.  Hori,  S.  Kokudo, T. 
Hamaoka, and H. Fujiwara. 1989. Tolerance  induction of  ailo- 
class I H-2 antigen-reactive Lyt-2  § helper T cells and pro- 
longed survival  of  the corresponding class I H-2-disparate skin 
graft, f  Immunol. 143:1. 
17.  Hori,  S.,  S.  Sato, S.  Kitagawa, T. Azuma,  S.  Kokudo, T. 
Hamaoka, and H. Fujiwara. 1989. Tolerance  induction of  ailo- 
class  II  H-2  antigen-reactive L3T4 +  helper T  cells and 
prolonged survival of the corresponding class II H-2-disparate 
skin graft. J. Imraunol. 143:1447. 
18.  Singer, A., T.I. Munitz, H. Golding, A.S. Rosenberg, and T. 
Mizuochi. 1987. Recognition requirements for the activation, 
differentiation and function of T-helper cells specific for class 
I MHC alloantigens. Iraraunol. Rev. 98:143. 
19.  Singer,  A., A.M. Kruisbeek, and P.M. Andrysiak. 1984. T cell 
accessory  ceil interactions that initiate allospecific  cytotoxic T 
lymphocyte responses: existence of both Ia-restricted and Ia- 
unrestricted cellular  interaction  pathways.J. IramunoL 132:2199. 
20.  Mizuochi, T., S. Ono, T.R. Malek, and A. Singer. 1986. Char- 
acterization of two distinct primary T cell populations that 
secrete interleukin 2 upon recognition ofchss I or class II major 
histocompatibility antigens, f  Ext~ Med. 163:603. 
21.  Dial)nag D.P., D.B. Wilde, P. Marrack, K.A. Pierces, A. Wall, 
A. Havan, G. Otten, M.R. Loken, M. Pierres,  J. Kappler, and 
F.W. Fitch. 1983. Characterization of the murine antigenic de- 
terminant, designated L3T4a, recognized by monodonal an- 
tibody GK1.5: expression  of  L3T4a by functional T cell clones 
appears to correlate primarily with class II MHC antigen- 
reactivity. Imraunol. Rev. 74:29. 
22.  Fujiwara, H., T. Hamaoka, G.M. Shearer, H. Yamamoto,  and 
W.D. Terry. 1980. The augmentation of in vitro and in vivo 
tumor-specific T cell mediated immunity  by amplifier T lym- 
phocytes, f  Immunol. 124:863. 
23.  Billingham, K.E., and P.B. Medawar. 1951. The technique of 
free skin grafting in mammals. J. Ext~ Med. 28:385. 
24.  Ly, I.A., and R.I. Mishell. 1974. Separation of mouse spleen 
cells by passage through columns  of  Sephadex G-10.J. Immunol. 
108  Call-Call  Interaction in Allograft Response Methods. 5:239. 
25.  Sugihara, S., Y. Izumi, T. Yoshioka, H. Yagi, T. Tsujimura, 
O. Tarutani, Y. Kohno, S. Murakami, and H. Fujiwara. 1988. 
Autoimmune thyroiditis induced in mice deleted of particular 
T ceil subsets. I. Requirement of Lyt-la~l-.3T4  ~Sht normal T 
cells for the induction of thyroiditis. J. Iraraunol. 141:105. 
26.  Kitagawa, S., S. Sato, T. Azuma, J. Shimizu, T. Hamaoka, 
and H. Fujiwara. 1991. Heterogeneity of CD4 + T cells in- 
volved in anti-allo-class I H-2 immune responses: functional 
discrimination  between the major proliferating  cells and helper 
cells assisting  cytotoxic T cell responses.J. Iraraunol. 146:2513. 
27.  Kimoto, M., and C.G. Fathman. 1980. Antigen-reactive  T cell 
clones. I. Transcomplementing hybrid I-A region gene prod- 
ucts function effectively  in antigen presentation.J. EXlX Med. 
152:759. 
28.  Sato, S., H. Iwata, S. Kitagawa, S. Kokudo, K. Okuno, T. 
Hamaoka, and H. Fujiwara. 1991. Lymphoid cell populations 
required for induction  of tolerance of different subsets of 
alloantigen-reactive  T cells. Transplantation (Baltimore). In press. 
29.  Kitagawa, S., H. Iwata, S. Sato,  J. Shimizu, T. Hamaoka, and 
H. Fujiwara. 1991. Heterogenous graft rejection pathways in 
class I major histocompatibility complex-disparate combina- 
tions and their differential susceptibility to immunomodula- 
tion induced by intravenous presensitization with relevant al- 
loantigens. J. EXl~ Meg  174:571. 
30. Golding, H., and A. Singer. 1985. Specifidty, phenotype, and 
precursor frequency  of  primary cytolytic  T lymphocytes  specific 
for class II major histocompatibility antigens. J.  Imraunol. 
135:1610. 
31.  Pierres, A., P. Naquet, A. van Agthoven, F. Bekkhoucha, F. 
Denizot, Z. Mishal, A. Schmitt-Verhulst,  and M. Pierres. 1984. 
A rat anti-mouse T4 monodonal antibody (H129.19) inhibits 
the proliferation of Ia-reactive  T cell clones and delineates  two 
phenotypically distinct (T4 +  , Lyt-2, 3-, and T4-, Lyt-2, 3 +) 
subsets among  anti-Ia cytolytic T  cell clones. J.  Iraraunol. 
132:2775. 
32.  Shinohara, N. 1987. Class II antigen-specific  murine cytolytic 
T lymphocytes (CTL). I. analysis  of bulk populations and es- 
tablishment of Lyt-2+L3T4  -  and Lyt-2-L3T4  + bulk CTL 
lines. Ceil. Iraraunol. 107:395. 
33.  Shinohara, N., J.A. Bluestone, and D.H. Sachs. 1986. Cloned 
CTL which recognize an I-A region product in the context 
of a class I antigen. J. Ex  F Med.  163:972. 
109  Hori et al. 